back to Canada directory
canada clinical guidance

Stable COPD maintenance pharmacotherapy

A Canadian Thoracic Society summary of maintenance pharmacotherapy for adults with confirmed stable COPD.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceCanadian healthcare professionals caring for adults with stable COPD
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply the complete symptom and exacerbation phenotype alongside current provincial or territorial access criteria.

Scope of this summary

Stable maintenance pharmacotherapy in adults with COPD. Acute exacerbations, oxygen, pulmonary rehabilitation and other nonpharmacologic management require separate pathways.
sources for this section:CTS 2023CTS library

Confirm and phenotype before escalating

1

Confirm COPD

Demonstrate persistent airflow obstruction with post-bronchodilator spirometry in the appropriate clinical context.
2

Measure symptom burden

Use a validated measure such as mMRC or CAT rather than impressions alone.
3

Establish exacerbation risk

Use the guideline definitions and recent history to separate lower- and higher-risk pathways.
4

Review fundamentals

Check smoking exposure, inhaler technique, adherence, comorbidities and nonpharmacologic care.
sources for this section:CTS 2023

Use the complete CTS phenotype

The CTS maintenance algorithm does not use symptoms alone. It combines symptom burden measured with mMRC or CAT, the guideline-defined exacerbation history and impaired lung function, including FEV1 <80% predicted, before selecting a regimen.

Use the complete source definitions and algorithm rather than inferring dual or triple therapy from an mMRC or CAT score alone. Balance any inhaled-corticosteroid benefit against pneumonia and other risks.

sources for this section:CTS 2023

Reserve add-on options for selected populations

  • Azithromycin only when the guideline phenotype, contraindication and monitoring requirements are met.
  • Roflumilast only for the source-defined phenotype and exacerbation history.
  • N-acetylcysteine only in the selected population described by the source.
  • Reassess diagnosis, exposure, technique, adherence and comorbidity before adding treatment.
sources for this section:CTS 2023

Treatments the CTS guideline recommends against

Do not use theophylline, maintenance systemic oral corticosteroids or inhaled corticosteroid monotherapy as routine stable-COPD maintenance treatment.
sources for this section:CTS 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Thoracic Society2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients with Stable COPDDOI 10.1080/24745332.2023.2231451 路 published 2023-09-08 路 accessed 2026-08-20
    view source
  2. Canadian Thoracic SocietyGuideline library: current respiratory guidelinescurrent status checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.